2021

• others2021/09/07

  The company overview was published in Farumashia, the journal of The Pharmaceutical Society of Japan

  The company overview written by Akihiro Furuta, President of AskAt Inc. was published in Farumashia (Vol. 57, No. 9.) , the journal of The Pharmaceutical Society of Japan.

• science2021/05/31

  Inhibitory effects of colon tumorigenesis byRQ-15986, AskAt’s EP4 antagonist, in APC-mutant rats was published in PLOS ONE

  Drs. Shirakami and Shimizu, Departments of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, discovered that RQ-15986/CJ-42,794, an AskAt’s EP4 antagonist having similar features with AAT-007/8 in discovery stage, demonstrates anti-tumor efficacy in rat colorectal cancer model, and published the results in PLOS ONE.

• business2021/05/25

  Oxford Cannabinoid Technologies Holdings PLC Debuts on London Stock Exchange on 21st May, 2021

  Oxford Cannabinoid Technologies Holdings Plc, the holding company of Oxford Cannabinoid Technologies Ltd (OCT), debuted on the Main Market of the LSEG (London Stock Exchange Group) on 21st May, 2021. OCT is a UK-based pharmaceutical company currently developing AAT-730 (OCT461201), a CB2 receptor agonist licensed from AskAt Inc.

• patent2021/05/25

  Galliprant Tablet® Granted Five-Year Patent Term Extension in Japan

  The Japan Patent Office granted a five-year patent term extension for Galliprant®, a veterinary therapeutic, on May 18, 2021. Elanco Japan K.K. (President: Philip Huggenberger, Elanco Japan) markets Galliprant® in Japan, and this action extends the period of exclusive sales rights until March 1, 2031.

• patent2021/05/14

  Canadian Intellectual Property Office (CIPO) Approves AskAt EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease

  AskAt received a notice of allowance dated April 20, 2021 of a use patent for its EP4 receptor antagonist in the treatment of cartilage disease. The notice was issued by the Canadian Intellectual Property Office (CIPO), in connection with Canadian Patent Application No. 2,907,049 (Filing Date: March 19, 2014). In addition to Canada, the use patent has been granted in Japan, Mexico, Russia, and the United States.

• patent2021/05/14

  China National Intellectual Property Administration (CNIPA) Grants AskAt a Patent for the Use of EP4 Receptor Antagonists in the Treatment of NASH-Associated Liver Cancer

  AskAt received a notice of allowance dated April 7, 2021 of a use patent for its EP4 receptor antagonist in the treatment of NASH-associated liver cancer. The notice was issued by the China National Intellectual Property Administration (CNIPA), in connection with Chinese Patent Application No. 201780004254.2 (Filing Date: November 2, 2017). In addition to China, the use patent has been granted in Canada, Europe, Japan, Mexico, and the U.S.

• patent2021/04/13

  National Institute of Industrial Property (Instituto Nacional da Propriedade Industrial: INPI) Approves Dementia Use Patent for AskAt’s 5-HT4 Receptor Agonist (AAT-009) in Brazil

  AskAt Inc. announced today that the company received a use patent allowance of its 5-HT4 receptor agonist (AAT-009) for dementia. Application No. BR112012020060.7 was published in Brazilian Industrial Property Journal (Official Gazette) No: 2621 on March 30, 2021. In addition to Brazil, the use patent has been granted in Canada, Europe, Japan, Korea, Mexico, Russia, and the U.S.

• business2021/04/08

  Capital Increase Report

  Capital Increase Report
  

• patent2021/04/07

  U.S. Patent Office Allows EP4 Receptor Antagonist Use Patent for Immuno-oncology Therapy

  AskAt Inc. received a notice of allowance from the U.S. Patent Office of a use patent for its EP4 receptor antagonist in immuno-oncology therapy (Appl. No. 16/385,524). AskAt and Arrys Therapeutics, a wholly owned subsidiary of Ikena Oncology ((NASDAQ: IKNA) headquartered in Boston, Massachusetts), jointly filed the patent application. The patent will remain effective until April 15, 2039.

• business2021/03/30

  IKENA Oncology Debuts on NASDAQ with over $1 Billion Market Capitalization

  Ikena Oncology, Inc. (IKNA), a targeted oncology company currently developing an EP4 antagonist (AAT-007) in the clinic originally licensed from AskAt Inc., debuted on the NASDAQ market on March 26, 2021. The company sold 7,812,500 shares at $16 each, then doubled in value over the first day of trading, closing at $32.

• ir2021/03/29

  8th period  financial statement release

  8th period  financial statement release

• business2021/03/29

  Ikena Oncology Inc. Debuts on NASDAQ

  Ikena Oncology, Inc. (https://ikenaoncology.com/ Boston, MA, USA; CEO Mark Manfredi, Ikena Oncology) debuted as a public company, listing its shares on the NASDAQ market on March 26, 2021. Ikena Oncology is currently eveloping AskAt’s EP4 antagonist, AAT-007, for immunooncology therapy in the US. For further details, please see Ikena’s announcement (Ikena Oncology Public Offering).

• patent2021/03/23

  Korean Intellectual Property Office Granted AskAt a Use Patent of EP4 Receptor Antagonist for the Treatment of Cartilage Disease

  AskAt Inc. announced today that AskAt received a notice of allowance dated March 10, 2021 from the Korean Intellectual Property Office in connection with the Application No. 10-2020-7024372, a use patent of EP4 receptor antagonist for the treatment of cartilage disease.